Daratummab has a good therapeutic effect on CLL through ADCC, CDC, and ADCP, and apoptosis mechanisms CD38 reduced the enhancement effect of ibrutinib on Syk, BTK, PLCγ2, ERK1/2, and AKT. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.